CombiMatrix On Path To Market Genomic Tests For Cancer, Retardation
This article was originally published in The Gray Sheet
Executive Summary
CombiMatrix Molecular Diagnostics (CMD) is looking to file with FDA for market approval of complex gene signature tests for cancer and mental retardation by the end of the year, according to the firm